342 results on '"Tafuto, Salvatore"'
Search Results
2. Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database
3. Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial
4. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
5. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
6. Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trial
7. Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group
8. A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice
9. Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours
10. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis
11. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study
12. Plexiform Fibromyxoma in the Stomach: Immunohistochemical Profile and Comprehensive Genetic Characterization
13. Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort
14. Corrigendum to “Sex differences on multikinase inhibitors toxicity in patients with advanced gastroenteropancreatic neuroendocrine tumours” [Eur J Cancer 188 (2023) 39–48]
15. The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives
16. Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival
17. Synovial Sarcoma of the Kidney: Diagnostic Pitfalls in a Case with Myxoid Monophasic Differentiation and No Epithelial Biomarkers Expression.
18. [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.
19. Is immunotherapy in the future of therapeutic management of sarcomas?
20. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations
21. Therapy for Metastatic Disease: Stomach/Duodenum, Colon/Rectum
22. Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
23. Prognostic Assessment of Gastropancreatic Neuroendocrine Neoplasm: Prospects and limits of Radiomics
24. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist’s challenge
25. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues
26. One‐way endobronchial valves in the management of complex persistent air leaks in a soft tissue sarcoma patient
27. Indications for Systemic Chemotherapy
28. [ 177 Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study.
29. Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival.
30. Prognostic and Predictive Role of CXC Chemokine Receptor 4 in Metastatic Colorectal Cancer Patients
31. Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours:findings from the phase II TALENT trial
32. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study
33. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study
34. Response to Peptide Receptor Radionuclide Therapy in Pheocromocytomas and Paragangliomas: A Systematic Review and Meta-Analysis
35. Diagnostic Management of Gastroenteropancreatic Neuroendocrine Neoplasms: Technique Optimization and Tips and Tricks for Radiologists
36. Everolimus and pancreatic neuroendocrine tumors (PNETs): Activity, resistance and how to overcome it
37. Electrochemotherapy as a new approach on pancreatic cancer and on liver metastases
38. The complex management of the breast angiosarcoma: a retrospective study
39. COVID-19 in patients with neuroendocrine neoplasms: two-year results of the INTENSIVE study
40. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives
41. Evaluation of MGMT Gene Methylation in Neuroendocrine Neoplasms [*Della Monica, R. e Cuomo, M. co-primi autori]
42. Therapy for Metastatic Disease: Stomach/Duodenum, Colon/Rectum
43. The Impact of O6-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation on the Outcomes of Patients with Leiomyosarcoma Treated with Dacarbazine.
44. A comparison of simplified protocols of personalized dosimetry in NEN patients treated by Radio Ligand Therapy (RLT) with [177Lu]Lu-DOTATATE to favour its use in clinical practice
45. Streptozotocin, 1982-2022 : Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors
46. A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice.
47. The Complex Management of the Breast Angiosarcoma: A Retrospective Study.
48. Additional file 7 of Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis
49. Additional file 3 of Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omics analysis
50. Sa1162 ITANET NATIONAL PROSPECTIVE DATABASE: A COMPREHENSIVE ANALYSIS OF EPIDEMIOLOGY AND CLINICAL PRESENTATION OF GEPNEN IN ITALY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.